MENLO PARK, Calif.,
Oct. 18, 2017 /PRNewswire/ --
BioPharmX Corporation (NYSE MKT: BPMX) will share research
suggesting that BPX-01, the company's topical gel formulation of
minocycline, may be useful in the treatment of inflammatory skin
diseases, including acne and papulopustular rosacea, particularly
as the medical community has growing concerns about antibiotic
resistance secondary to systemic exposure.
A presentation at the Re-entering Antibacterial Discovery and
Development Summit on Oct. 18-20 in
Boston concludes that minocycline
is effective in fighting gram-positive and gram-negative bacteria,
as well as other micro-organisms implicated in rosacea and acne –
while also alleviating the inflammation they cause. Many antibiotic
therapies used today fight bacteria in the skin, but do little to
alleviate the inflammation or the associated discomfort.
The poster, entitled "Development of Minocycline (BPX-01) as a
Topical Treatment for Acne Vulgaris and Rosacea," reports that
pre-clinical study findings of no or low erythema suggest that
topical administration of minocycline may be useful for the
treatment of inflammatory skin diseases. It also reports that
BPX-01 topical minocycline was well tolerated among clinical trial
participants and that more than 85 percent of subjects said they
would use it again.
BioPharmX is the first company to develop an effective topical
formulation of minocycline thereby taking full advantage of its
potential in treating inflammatory skin diseases while minimizing
systemic exposure. BPX-01 is the first topical gel formulation of
minocycline that can penetrate the skin to deliver the antibiotic
to the pilosebaceous unit, where acne- and rosacea-associated
inflammation develops. It is also the first and only stable
hydrophilic and non-oil-based topical gel comprising of fully
solubilized minocycline, rather than crystal suspension of
the active ingredient.
"Research shows BPX-01 unleashes the potential therapeutic
advantages of minocycline for the treatment of acne and rosacea by
efficient delivery to the area of the skin where these diseases
emerge," said Kin F. Chan, PHD, executive vice president of
research and development at BioPharmX.
The company's clinical studies are designed to confirm whether
BPX-01 can effectively treat acne and rosacea with lower, safer
dosages of the antibiotic.
About BPX-01
BPX-011 is a hydrophilic
(non-oil-based) topical gel with fully solubilized minocycline that
has been shown to penetrate the skin to deliver the antibiotic to
its target. Following positive results from its previously
announced phase 2b study of BPX-01 in acne, BioPharmX continues
with phase 3 clinical study plans for BPX-01 for the treatment of
acne.
About BioPharmX® Corporation
BioPharmX
Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty
pharmaceutical company, which seeks to provide products through
proprietary platform technologies for prescription,
over-the-counter (OTC), and supplement applications in the health
and wellness markets, including dermatology and women's health. To
learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. This press release contains forward-looking statements
about the company's expectations, plans, intentions, and
strategies, including, but not limited to, statements regarding the
safety and medical effects of BPX-01, the effect BPX-01 may have on
the treatment of acne, the commencement and results of future
trials of BPX-01 and the size of such trials, continued and
consistent results in future tests of BPX-01 and absence of side
effects of future use of BPX-01. These forward-looking statements
may be identified by words such as "plan," "expect," "anticipate,"
"believe" or similar expressions that are intended to identify such
forward-looking statements.
These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ
materially from those expressed or implied by such forward-looking
statements. The risks and uncertainties include those described in
the company's filings with the Securities and Exchange Commission,
including our annual report on Form 10-K for the period
ended Jan. 31, 2017. Given these risks and uncertainties, you
are cautioned not to place undue reliance on such forward-looking
statements. The forward-looking statements included in this news
release are made only as of the date hereof, and the company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities law.
BioPharmX is a registered trademark of BioPharmX, Inc.
1Caution:
BPX-01 is a new drug limited by U.S. law to investigational
use.
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/biopharmx-to-present-at-re-entering-antibacterial-discovery-and-development-summit-2017-300538255.html
SOURCE BioPharmX Corporation